Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs

Journal

• Arthritis Rheum.

  Arthritis Rheum. 58 2968-2980, 2008